Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Raises Price Target to $97

Benzinga · 1d ago
Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $95 to $97.